Feature | HRS | May 16, 2017

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

HRS presentations include data on the S-ICD, Micra, Nanostim, PV isolation, lead extractions and pharma

An electrophysiology EP ablation procedure to treat a heart arrhythmia

May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 annual meeting May 10-13, in Chicago. The data presented is for the latest in electrophysiology (EP) clinical research, techniques and technologies. These trials were featured at Heart Rhythm 2017 and will be published in the July issue of the Heart Rhythm Journal. 

Late-breaking Studies Presented at HRS 2017:

• The S-ICD Post-market Approval Study

Intra-nasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial

A Leadless Pacemaker In The Real-world Setting: The Micra Transcatheter Pacing System Post-approval Registry

• EWOLUTION trial: 1-Year Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation

High Incidence Of Previously Unknown (“Silent”) Atrial Fibrillation In Patients At High Risk For Atrial Fibrillation And Stroke: Primary Results From The REVEAL AF Study

Compliant Endovascular Balloon Reduces the Lethality of Superior Vena Cava Tears During Transvenous Lead Extractions

First-in-man Feasibility Study Of Subcutaneous Defibrillation Utilizing An Integrated Flexible String Shaped Defibrillator

PV Isolation With A Novel Multielectrode Radiofrequency Balloon Catheter That Allows Directionally-tailored Energy Delivery (RADIANCE): A Multicenter First-in-man Experience

• A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU (Apixaban Evaluation Of Interrupted Or Uninterrupted Anticoagulation For Ablation Of Atrial Fibrillation) Trial

• Long Detection Programming In Single Chamber Defibrillators Reduces Unnecessary Therapies And Mortality: The Advance III Trial

• SPECT-guided Left Ventricular Lead Placement For Improved CRT Efficacy: A Randomized Controlled Trial

• Ranolazine in High-Risk ICD Patients (RAID) Trial

• Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment In Subjects With Recurrent Atrial Fibrillation: Results From The Powder AF Multicentre Randomised Trial

• The Nanostim Leadless Pacemaker: Battery Failures and Worldwide Chronic Device Retrieval

 

Other Key Presentations:

VIDEO: Editor's Choice of Most Innovative New Technology at HRS 2017

VIDEO: EP Lead Extraction Strategies, interview with Bruce Wilkoff, M.D.

VIDEO: Current State of Leadless Pacemaker Technology, interview with Vivek Reddy, M.D.

VIDEO: Overview of Subcutaneous ICD Technology

VIDEO: How to Start an Electrophysiology Program

Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation

Expert Consensus on MRI and Radiation Exposure in Patients With Implantable Cardiac Electronic Devices

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins.

Watch the VIDEO interview with HRS President Michael Gold, M.D., on latest EP technology trends

 

 

For more information: www.hrssessions.org

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init